Floatz logo

TAMOXIFEN

Estrogen Receptor Positive Tumor

Gangnam Severance HospitalSmall moleculePhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Estrogen Receptor Positive Tumor cohort.

Asset / SponsorPhaseRating
Zoladex
Gangnam Severance Hospital
Phase 4BB
LEUPROLIDE
Gangnam Severance Hospital
Phase 4BB
Lipitor
Aarhus University Hospital
Phase 3B
ERIBULIN MONOMETHANESULFONATE
Eisai Inc.
Phase 2B
Letrozole
ETOP IBCSG Partners Foundation
Phase 2B

View all 23 →

Same molecule, other indications

TAMOXIFEN is also rated in:

estrogen-receptor positive breast cancerDormant
BBB
Indicative ·
77 / 100
View asset →
breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →
invasive breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →